Recombinant Mouse IFN-alpha 13 Protein, CF

Recombinant Mouse IFN-alpha 13 Protein (10481-IF) suppresses viral activity on L-929 mouse fibroblast cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 1-15 ng/mL.

2 μg/lane of Recombinant Mouse IFN-alpha 13 (Catalog # 10481-IF) was resolved withSDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized byCoomassie® Blue staining, showing bands at kDa.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse IFN-alpha 13 Protein, CF Summary

• Details of Functionality: Measured in an anti-viral assay using L‑929 mouse fibroblast cells infected with encephalomyocarditis (EMC) virus. Vogel, S.N. et al. (1982) Infect. Immunol. 38:681. The ED₅₀ for this effect is 1-15 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived mouse IFN-alpha 13 protein
  Gly23-Glu189
• Accession #: Q80SU4.1
• N-terminal Sequence: Gly23
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 19 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 20-30 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse IFN-alpha 13 Protein, CF

• IFL
• IFNA1
• IFNA13
• IFNalpha 13
• IFN-alpha 13
• IFN-alpha 1b
• IFN-alpha-1/13
• interferon alpha-1/13
• Interferon alpha-D
• interferon, alpha 13
• LeIF D

Background

Interferon-alpha 13 (IFN alpha -13), also known as IFN alpha -1/13 and LeIF D, is one of 14 subtypes within the IFN-alpha family (1). Interferons are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). The members of the IFN-alpha family are distinct but closely related proteins sharing approximately 80% amino acid (aa) sequence identity and a globular structure composed of five alpha-helices (1-3). The mature extracellular domain (ECD) of mouse IFN alpha -13 is shares 64% aa sequence identity with human IFN alpha -13. IFN-alpha family members signal through a common set of cell surface receptor complex composed of IFN alpha -R2 and IFN alpha -R1 subunits (2). Individual IFN-alpha subtypes are known to display unique efficacies to viral protection, and IFN alpha -13 displays antiviral activity protective against Theiler's virus, Mengo virus, VSV (4). IFN alpha -13 reproducibly appears to be up-regulated in response to TMEV infection (5). IFN alpha -13 also protects L929 cells against EMCV as tested in our assays.

1. Moulton, V. R. (2016) Systemic Lupus Erythematosus, 137-141.
2. Oritani, K. et al. (2001). Cytokine & Growth Factor Reviews, 12:337.
3. Pesch, V. et al. (2004). Journal of Virology, 78:8219.
4. Pesch, V. et al. (2004). Journal of Biological Chemistry, 21:46321.
5. Pesch, V. et al. (2001). Journal of Virology, 75:7811.

Bioinformatics

• Uniprot:
  • Q80SU4.1()